[Clinical and pathological prognostic factors for XXXX of the esophagogastric junction].

@entity5 @entity1 @entity420 @entity418
INTRODUCTION: @entity420 ( @entity420 ) is a particular @entity5 entity because two substantially different surgical procedures are required according to the location. There is no difference in long-term prognosis between the @entity5 types in spite of the different surgical procedures. We were interested to evaluate the clinical and pathological prognostic factors of the AEGs which were operated in our department. @entity1 AND METHODS: 108 @entity1 were operated for @entity420 between 1.1.2000 and 1.4.2006 in our institution. 32 (29.6 %) @entity1 with @entity418 (type I according to Siewert) underwent a transthoracic esophagectomy with gastric pull-up and two-field lymphadenectomy. 57 (52.8 %) @entity1 with type II and 19 (17.6 %) @entity1 with @entity5 received an extended gastrectomy with D2 lymphadenectomy. The retrospective analysis was focused on clinical and pathological parameters. Possible differences between the @entity5 types were also evaluated. Median follow-up was 11.4 months (range: 1-57 months). RESULTS: Follow-up data were complete for 107 @entity1 . A median survival of 17.4 +/- 3.25 months and a cumulative survival of 30 % were independent of the @entity5 location and the surgical procedure. Overall hospital mortality was 3.7 %. The univariate analysis showed that survival was significantly associated with the T category, lymph node status, lymphangio- and angioinvasion and @entity5 grading. In the multivariate analysis, only lymph node status was identified as an independent prognosis factor for survival. Where-as the R status was not a prognostic factor per se, how-ever, @entity1 with an R0 situation without lymphangio- and angioinvasion had a significantly better survival compared to all other @entity1 (p = 0.001). An increased angioinvasion rate was observed in @entity5 (52.6 %) in comparison to type I (21.9 %) and type II (21.1 %) @entity5 . CONCLUSION: The prognostic factors of our @entity1 determined substantially the prognosis of the @entity1 . @entity1 with lymph- or haemangioinvasion should regarded as high-risk @entity1 independent of the R status. Close oncological follow-up including potential adjuvant treatment in these @entity1 is recommended.
